The U.S. FDA has approved Johnson & Johnson’s INLEXZO™ (gemcitabine intravesical system) for adults with BCG-unresponsive non ...

In the absence of large RCTs comparing TMT versus RC for MIBC, investigators conducted a systematic review and meta-analysis.

Investigators compared survival among patients with limited-stage small cell bladder cancer receiving different treatment approaches.

enGene Holdings Inc. ( NASDAQ: ENGN) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:50 PM EDT ...

Traditional treatment for NMIBC includes transurethral resection of bladder tumor (TURBT), or standard resection (SR), allowing for the resection of all observable tumors without disruption to the ...

Intravesical cretostimogene is administered in combination with n-dodecyl-β-D-maltoside (DDM), an excipient that enhances adenoviral delivery, for 6 weekly doses during the induction phase, followed ...

1Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, Maryland.

Data from the SunRISe-1 trial showed a complete response rate of 82%, with 51% of patients remaining in complete response for at least 1 year.